Campina Grande

Researchers are evaluating the effects of implantable Gestrinone compared to oral Dienogest in adult female patients aged 18 to 45 years with endometriosis. This randomized controlled trial aims to relieve symptoms related to endometriosis, such as dysmenorrhea, dyspareunia, and non-cyclical pelvic pain, while assessing quality of life and sexual function. The study is conducted across private medical clinics in multiple cities and includes 70 participants divided equally into two groups. One group will receive implantable Gestrinone pellets subcutaneously in the gluteal region, dosed at 1.6 mgkg of body weight, with a second implantation at 6 months to evaluate effects over 12 months. The other group will take oral Dienogest at 2 mg daily for 12 months. Both treatments will be monitored through scheduled follow-up visits at 1 week, and 1, 3, 6, 9, and 12 months after starting therapy. Participants will undergo assessments of pain severity using verbal and visual scales, uterine bleeding levels, systemic effects by blood tests, endometrial thickness by ultrasound, body composition, and sexual function questionnaires. Researchers will also evaluate endometriosis lesions and quality of life over the study period. Data analysis will include comparisons between groups and repeated measures over time, with safety and adverse effects monitored throughout the trial.

This research aims to evaluate the effects of lowering blood phosphate levels in adults with end-stage kidney disease ESKD who are receiving dialysis. Elevated phosphate levels are common in ESKD and linked to higher risk of death and heart problems, but it is unclear if reducing phosphate improves important patient outcomes. The study will compare intensive lowering of phosphate to a more liberal phosphate target to see if this reduces heart-related deaths and events, improves physical health, and is cost-effective. Participants will be randomly assigned to one of two groups one aiming for a liberal serum phosphate target of 2.0 to 2.5 mmolL, and the other aiming for an intensive target of 1.50 mmolL or lower. Doctors will decide the type and dose of phosphate-lowering medications to help participants reach their assigned phosphate levels, following usual local practices. The study will last up to five years and is conducted internationally with 3600 adults on dialysis. During the study, researchers will monitor participants for major heart-related events and deaths, physical health, fatigue, quality of life, patient satisfaction, and itching. Regular assessments will include measuring time to cardiovascular death or major cardiovascular events and evaluating overall survival and quality of life using the EQ5D-5L tool. The study will also assess cost-effectiveness and continue to observe participants for five years to collect comprehensive data on these outcomes.